Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.
Valsartan−Rückruf − Auswirkungen und Implikationen für die Zukunft
AGES Medizinmarktaufsicht
Array
(
[0] => post
[1] => custom_css
[2] => customize_changeset
[3] => oembed_cache
[4] => user_request
[5] => ap-punkte
[6] => apotheker-krone
[7] => apokolleg
[8] => apo-raetsel
[9] => aerzte-krone
[10] => diabetes-forum
[11] => faktenrheumatologie
[12] => fokus
[13] => gyn-aktiv
[14] => klinik-ausgaben
[15] => das-medizinprodukt
[16] => nephro-script
[17] => neue-horizonte
[18] => neurologisch-ausg
[19] => pn
[20] => medizin-verstehen
[21] => pharm-austria
[22] => die-punkte
[23] => spectrumdermatologie
[24] => spectrum-onkologie
[25] => spectrum-osteoporose
[26] => spectrum-psychiatrie
[27] => spectrum-urologie
[29] => zahn-krone
[30] => zahn-punkte
[31] => arzt-und-praxis
[32] => apoteam
[33] => nl-banner
[34] => spectrum-pathologie
[35] => ahop
[36] => diepunkteon
[37] => diepunkteon-aktuell
[38] => diepunkteonpages
[39] => spio
[40] => spio-tumor
[41] => spio-substanz
[42] => molonko-target
[43] => molonko-indication
[44] => molonko-substance
[45] => molonko-product
[46] => personen
[47] => nextdoc
[48] => nextdoc_job
[49] => nextdoc_employer
[50] => nextdoc_employersub
[51] => relatus-med
[52] => relatus-pharm
[53] => congress-x-press
[54] => cxp-article
[55] => acf-field-group
[56] => acf-field
[57] => bp-email
[58] => experts
)
